A study of the immune infiltrate and patient outcomes in esophageal cancer
- 17 September 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Carcinogenesis: Integrative Cancer Research
- Vol. 42 (3), 395-404
- https://doi.org/10.1093/carcin/bgaa101
Abstract
Cancer patient outcomes and selection for novel therapies are heavily influenced by the immune contexture of the tumor microenvironment. Esophageal cancer is associated with poor outcomes. In contrast to colorectal cancer, where the immunoscore is increasingly used in prognostic staging, little is known about the immune cell populations in esophageal adenocarcinoma (EAC) and esophageal squamous cell carcinoma (SCC), and their clinical significance. Tissue microarrays were constructed from resected tumor tissue of 72 EAC patients and 23 SCC patients. Immunohistochemical staining of CD3, CD8, CD56, CD68, CD45RO, CD69, IFN-γ, IL-10, IL-4, IL-17, TGF-β, FOXP3 and CD107a was performed. Positivity was examined in both the stromal and epithelial compartments. Statistical analysis was performed to identify differences in immune cell infiltration and functional phenotypes between cancer subtypes and tissue compartments. This study identified that esophageal tumors are enriched with CD45RO + and CD8 + cells and such positivity is significantly higher in SCC compared to EAC. Furthermore, the expression of CD45RO positively correlates with that of CD8 within the tumors of both patient cohorts, suggesting a dominance of memory cytotoxic T cells. This is supported by strong positivity of degranulation marker CD107a in the stromal compartment of EAC and SCC tumors. Cytokine staining revealed a mixed pro- and anti-inflammatory profile within EAC tumors. Esophageal tumors are enriched with memory cytotoxic T cells. Applying these measurements to a larger cohort will ascertain the clinical utility of assessing specific lymphocyte infiltrates in EAC and SCC tumors with regards to future immunotherapy use, patient prognosis and outcomesKeywords
Funding Information
- Health Research Board of Ireland’s Health Research Award (PD/2009/35)
This publication has 27 references indexed in Scilit:
- Prognostic value of tumor infiltrating NK cells and macrophages in stage II+III esophageal cancer patientsOncotarget, 2016
- Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trialThe Lancet Oncology, 2016
- Abundant PD-L1 expression in Epstein-Barr Virus-infected gastric cancersOncotarget, 2016
- Patterns of PD-L1 expression and CD8 T cell infiltration in gastric adenocarcinomas and associated immune stromaGut, 2016
- Mismatch repair deficiency may affect clinical outcome through immune response activation in metastatic gastric cancer patients receiving first-line chemotherapyGastric Cancer, 2016
- Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinomaCancer Letters, 2016
- Epithelial PD-L2 Expression Marks Barrett's Esophagus and Esophageal AdenocarcinomaCancer Immunology Research, 2015
- Neoadjuvant chemoradiotherapy for resectable esophageal cancer: an in-depth study of randomized controlled trials and literature review2014
- Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumoursThe Journal of Pathology, 2013
- MAGE-A3/4 and NY-ESO-1 antigens expression in metastatic esophageal squamous cell carcinomaEuropean Journal of Histochemistry, 2011